Taro Pharmaceutical Industries Ltd.
https://www.taro.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Taro Pharmaceutical Industries Ltd.
Taro Agrees $36m Securities Settlement Over US Price-Fixing Claims
Sun’s Taro subsidiary is looking to move forward with an eight-figure settlement deal in the US, after plaintiffs including a firefighters’ pension fund accused the firm of misleading investors via its involvement in generic price fixing, leading to a fall in the price of its securities.
Deal Watch: Bristol To Link Up With VantAI On Molecular Glue Therapies
Plus deals involving BioVaxys/IMV, Immunome/Ayala, Nascent/Manhattan BioSolutions, AVROBIO/Tectonic, Sanofi/Synthekine, NAYA/Florida Biotechnologies as well as deals in brief and tech transfer agreements.
Sun Set To Get Taro Deal Over The Line, 17 Years After First Trying
More than a decade after a renewed bid to take control of Taro failed, Sun Pharma is set to take full control of the Israeli-based derma specialist, which has seen material growth and much controversy in the US under Sun’s ownership.
US FDA Adds Capacity For Bioequivalence Studies That Could Help Build Trust In Generics
Agency will fund clinical studies to answer complaints of generic inequivalence and resolve scientific controversies over methods used to support approval.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
- OTC, Consumer
- Other Names / Subsidiaries
-
- Thallion Pharmaceuticals, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice